After Canaccord Genuity and Piper Sandler gave Crispr Therapeutics AG (NASDAQ: CRSP) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Silvan Tuerkcan maintained a Buy rating on Crispr Therapeutics AG today and set a price target of $80.00. The company’s shares closed last Wednesday at $52.00.
According to TipRanks.com, Tuerkcan is a 5-star analyst with an average return of 38.6% and a 81.5% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intellia Therapeutics, and Seattle Genetics.
Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $71.68, a 34.6% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
Crispr Therapeutics AG’s market cap is currently $3.2B and has a P/E ratio of 56.10. The company has a Price to Book ratio of 3.57.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.